Valion Bio, Inc. is classed by the SEC under Electromedical & Electrotherapeutic Apparatus (industry code 3845), based in San Antonio, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $780 thousand and a loss of $9 million (its filed statements).
Product businessElectromedical & Electrotherapeutic ApparatusSan Antonio, TXfilings since 20197 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3845, Electromedical & Electrotherapeutic Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.4 out of ten, 7 of 9 metrics filed and 2 estimated: past 2.3 out of ten, present 2.3 out of ten, future 6.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 4.1 out of ten. 6 warning events since 2019; the latest 2026-03-20. 41st percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 1.4 out of ten. -14.7% a year over 4 filed years; profitable in 0 of 4. 14th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 1.3 out of ten. CrossAssetData estimate 1.3/10, confidence 35 of 100 (one part). 13th percentile among 27 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 3.9 out of ten. ROE -53%: lost 53¢ per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar. 39th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 1.2 out of ten. bottom 12% of 24 in its family; net margin -725%. 12th percentile among 24 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 0.9 out of ten. bottom 9% of 19 in its family for leadership; chief executive since 2026. 9th percentile among 19 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 8.3 out of ten. CrossAssetData estimate 8.3/10, confidence 35 of 100 (one part). 83rd percentile among 27 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Growth drivers (future): 5.0 out of ten. bottom 50% of 25 in its family for growth drivers. 50th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 3.0 out of ten. bottom 30% of 20 in its family for expectations against reality. 30th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-30 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-14 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-05-14 (on EDGAR). Newest filing: Form 8-K, 2026-10-08. Filings on record since 2019. Read from EDGAR 2026-10-12.
Who runs it
Zikria, Dean (Interim CEO); Handley, Michael K (Chief Executive Officer); Ernst, Jennifer (Chief Executive Officer); Wolf, Lisa G (COO & CFO); Lackey, Melinda (General Counsel & SVP of Legal); Jensen, Thomas (director); Malbin, Jared David (director); Bolton, Sheryle (director); Valauri, Christina Rizopoulos (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.